355 results about "Inosine" patented technology

There is provided methods and compositions for the storage of red blood cells. The compositions are metabolic supplements which are preferably added to refrigerated red blood cells suspended in an additive solution. Red blood cells are preferably stored under conditions of oxygen-depletion. Metabolic compositions comprises pyruvate, inosine, adenine, and optionally dibasic sodium phosphate and / or monobasic sodium phosphate.

A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind, and (b) conjugated to the compound, an arginine-rich peptide effective to enhance the uptake of the compound into target cells. The string of bases in the compound includes at least one inosine base positioned in the string so as to limit the number of contiguous guanine bases in said string to three or fewer. The conjugate has greater cellular uptake than the compound alone, by virtue of the arginine-rich peptide, and substantially greater antisense activity greater activity than the conjugate in the absence of inosine-for guanine substitutions.

Provided herein are nucleic acid synthesis methods and agents that employ an endonuclease for example, endonuclease V, to introduce a nick into a target DNA including one or more inosine, and uses a DNA polymerase to generate amplicons of the target DNA.

Methods for detecting genomic rearrangements are provided. In one embodiment, methods are provided for the use of paired end tags from restriction fragments to detect genomic rearrangements. Sequences from the ends of the fragments are brought together to form ditags and the ditags are detected. Combinations of ditags are detected by an on-chip sequencing strategy that is described herein, using inosine for de novo sequencing of short segments of DNA. In another aspect, translocations are identified by using target specific capture and analysis of the captured products on a tiling array.

The invention relates to a preparation method of capecitabine and an intermediate thereof. The material conversion rate is high with less side reaction under the condition that bicarbonate is used as alkali by changing the reaction condition of synthesizing a compound of a formula I by a 5'-deoxidized-5-gemcitabine derivative and chloroformic acid n-amyl ester. Meanwhile, the applicant researches and finds that: Since 5-deoxidized-tri-O-acetyl-D-ribose prepared by using inosine reactrion substituted by iodine and protected by hydroxyl is adopted, the post-treatment process is simplified, and the yield is improved. The 5-deoxidized-tri-O-acetyl-D-ribose is a material for synthesizing the compound of the formula I while the compound of the formula I is a significant intermediate of capecitabine. The whole capecitabine synthesis process has high yield and low cost.

The invention relates to a rythrocyte lyophilized protective agent and a using method thereof during lyophilizing. The prescription of the protective agent before being lyophilized is as follows: glucose solution, adenine, NaCl, mannitol, KCl, polymer hydroxyethyl starch, bovine serum albumin and sodium citrate. The prescription of the lyophilized rehydration protective agents is as follows: trehalose, ascorbic acid, NaCl, KH2PO4, Na2 HPO4, dextran, bovine serum albumin, KCl, inosine and adenine. The protective liquid before being lyophilized and rythrocyte suspension liquid are mixed according to the volume ratio of 4:1, are frozen and dried to obtain lyophilized rythrocyte, then the lyophilized rythrocyte is rehydrated by the rehydration protective agent. The recovery rate of the rythrocyte lyophilized protective agent and the using method thereof during lyophilizing of the invention can reach as high as 71.1 percent through the measurement of a cell counter, and is improved by 12.3 percent by comparing with the lyophilized protective agent and the lyophilized method thereof in the prior art, the highest recovery rate of which is 58.5 percent.

The present invention provides a method for producing an inosine derivative represented by the following general formula (1) including the steps of subjecting an inosine derivative of general formula (3) to dithiocarbonylation and carrying out radical reduction of the obtained compound. According to the present invention there can be produced compounds useful as anti-AIDS drugs on industrial scale. wherein R1 may be the same or different and are each benzyl group, benzhydryl group or trityl group, each of which may have a substituent in general formulas (1) and (3).

The invention discloses an anti-alopecia composition and application thereof in preparation of anti-alopecia personal care products. The anti-alopecia composition comprises inosine, lupine hydrolyzedprotein and caffeine in a mass ratio of 1:(1-20):(1-5). The anti-alopecia composition has a remarkable anti-alopecia effect due to the cooperative use of the inosine, the lupine hydrolyzed protein andthe caffeine; the composition also has a hair growth promoting effect, wherein the principle is that hair follicle cells on the scalp are simulated to make the hair follicle cells in the period of dormancy regrow and the number of hair follicles in the growth period is increased to achieve the hair growth effect.

The present invention provides a method for treating and / or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and / or inosine.

The invention relates to a pharmaceutical composition for treating hepatic fibrosis and a preparation method thereof. The pharmaceutical composition is a formulation prepared from a main ingredient and pharmaceutically acceptable auxiliary materials, wherein the main ingredient comprises 100-300 parts of pirfenidone and 50-150 parts of inosine. The formulation of pirfenidone and inosine is stable in quality, controllable, safe and effective. In clinic, the formulation is mainly used for the treatment of diseases of hepatic fibrosis, cirrhosis, liver cancer, and the like.

The invention discloses a worm grass wine and preparation process, wherein, the worm grass wine belongs to the health medicine wine. The preparation process includes that: the worm grasses are bred in various wine containers through artificial fungus inoculation and moss silk reproduction by taking advantage of artificial broth bases, and then are added with wine to produce the worm grass wine. The worm grass wine includes 21 trace elements, a plurality of vitamins, cordycepin, cordycepicacid (d-mannitol), SOD enzyme, nucleic acid derivatives, uracil, adenine, inosine and ergo-sterol, and the content of the protein is 1.6 times that of the worm grasses. The worm grass wine can keep the worm grasses fresh, ensures the nourishment is not destructed and lost; moreover, the formation of the worm glass wine is beautiful and vivid like living creatures in the water due to the fact that the worm glass wine is bred in wine bottles through artificial broth bases with high values of medicine, appreciation, collection and so on.

A method of amplifying RNA template is provided. The method comprises reverse-transcribing a ribonucleic acid (RNA) template to form a cDNA using a first reaction mixture comprising RNA template, at least one primer capable of hybridizing to the RNA template, a reverse transcriptase and deoxynucleoside triphosphates (dNTPs); and amplifying the cDNA to form an amplified product using a second reaction mixture comprising at least one strand displacement DNA polymerase, at least one inosine-containing primer and a nuclease that is capable of nicking DNA 3' to an inosine residue of the primer. The method is accomplished under an isothermal condition without denaturing the cDNA template. A method of quantifying RNA template in a sample and a method of detecting RNA template in a sample are also provided. Kits for amplifying deoxynucleic acid (DNA) from ribonucleic acid (RNA) template are also provided.